Source comparison
Published Research on Tesamorelin vs CJC-1295 Ipamorelin
The research landscape for tesamorelin vs CJC-1295 Ipamorelin is asymmetric in terms of clinical evidence volume. Tesamorelin carries a uniquely strong data package as the only FDA-approved GHRH peptide, while CJC-1295 and Ipamorelin have well-established Phas
This comparison does not assign a generated winner or score.
- The research landscape for tesamorelin vs CJC-1295 Ipamorelin is asymmetric in terms of clinical evidence volume. Tesamorelin carries a uniquely strong data package as the only FDA-approved GHRH peptide, while CJC-1295 and Ipamorelin have well-established Phase I/II data supporting their individual mechanisms. Researchers comparing these compounds must account for this difference when designing studies or interpreting outcomes relative to the existing tesamorelin vs CJC-1295 Ipamorelin published literature.
- Tesamorelin clinical research: The pivotal Phase III trials (LIPO-010 and LIPO-011) enrolled 806 participants across 12 research centers over 26–52 weeks. Key findings: 15.4% reduction in visceral adipose tissue at 26 weeks (p<0.001); 65.8% mean increase in IGF-1; improvement in trunk-to-limb fat ratio; and maintenance of visceral fat reduction through a 52-week extension study.
- A meta-analysis of five randomized controlled trials (Dhaliwal et al., 2011) confirmed visceral fat reduction as a consistent, reproducible primary endpoint across diverse populations. The Framingham risk score improvement observed in some subgroups added cardiovascular relevance to the core data, further differentiating tesamorelin in the tesamorelin vs CJC-1295 Ipamorelin clinical evidence comparison.
- CJC-1295 and Ipamorelin research data: Teichman et al. (2006) showed CJC-1295 at 30–60 mcg/kg produced GH increases of 2–10x baseline with IGF-1 elevations of 1.5–3x baseline sustained for 6 days after a single injection. Ipamorelin Phase I data (Raun et al., 1998) demonstrated GH release at 1–10 mcg/kg with less than 10% change in cortisol or prolactin — superior selectivity versus all older GHRPs studied.
- Combined CJC-1295/Ipamorelin lacks Phase III data, but the pharmacological synergy is well-supported by the independent mechanism data for both components. Researchers can review relevant published GH secretagogue data via PubMed GH secretagogue literature.